Tapahtumakalenteri (vanha)

Avi Schroeder is a Professor of Chemical Engineering at the Technion–Israel Institute of Technology, where he heads the Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies.

Dr. Schroeder conducted his PhD studies jointly at the Hebrew and Ben Gurion Universities, and postdoctoral studies at MIT under the guidance of Prof. Langer.     

Avi has received more than 40 national and international recognitions, including being named a KAVLI Fellow and a fellow of the Royal Society of Chemistry, and winning the Intel Nanotechnology-, TEVA Pharmaceuticals-, and the Wolf Foundation Krill Awards. Avi is the author of over 80 papers and inventor of 23 patents. Avi is a co-founder of multiple startup companies based on these discoveries.

Dr. Schroeder is a former member of the Israel’s Young National Academy of Sciences, is a current member of Israel’s National Council for Civilian Research and Development, and is currently serving as the President of the Controlled Release Society (CRS).

Presentation Abstract

Nanotechnology holds numerous potential benefits for treating disease, including the ability to transport complex molecular cargoes, including RNA and proteins, and targeting specific tissues, including the brain. Brain-targeted nanoparticles enhance the delivery of monoclonal antibodies (mAbs) across the blood-brain barrier (BBB) and into neurons, thereby allowing the intracellular and extracellular treatment of Parkinson’s disease. 100-nm BTL cross human BBB models intact and are taken up by primary neurons. Within neurons, SynO4 is released from the nanoparticles and bound to its target - alpha-synuclein (AS), thereby reducing AS aggregation, and enhancing neuronal viability. In vivo, intravenous administration results in a seven-fold increase in mAbs in brain cells, decreasing AS aggregation and neuroinflammation and improving mice's behavioral motor function and learning ability. Targeted nanotechnologies offer a valuable platform for drug delivery to treat brain neurodegeneration.

The evolution of drug delivery systems into synthetic cells, programmed nanoparticles with an autonomous syn-bio capacity to synthesize diagnostic and therapeutic proteins inside the body, and their promise for treating disease will be discussed.